Wolfgang Merkt

Duesseldorf, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.

Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.

Journal: Science translational medicine

Published: May 13, 2026

Arthralgia and clubbing of the fingers lead to diagnosis of bronchial carcinoma

Arthralgia and clubbing of the fingers lead to diagnosis of bronchial carcinoma

Journal: Zeitschrift fur Rheumatologie

Published: September 30, 2025

Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis.

Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis.

Journal: Annals of the rheumatic diseases

Published: September 03, 2025

68Gallium-labelled fibroblast activation protein inhibitor uptake in joints: a single-center cohort analysis of 268 patients.

68Gallium-labelled fibroblast activation protein inhibitor uptake in joints: a single-center cohort analysis of 268 patients.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 07, 2025

Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis.

Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis.

Journal: Journal of innate immunity

Published: August 02, 2025

Experiences after CD19-CAR T-cell therapy in non-SLE connective tissue diseases

Experiences after CD19-CAR T-cell therapy in non-SLE connective tissue diseases

Journal: Zeitschrift fur Rheumatologie

Published: July 05, 2025

Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.

Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.

Journal: Rheumatology (Oxford, England)

Published: June 29, 2025

Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.

Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.

Journal: Nature medicine

Published: June 20, 2025

Efficacy of obinutuzumab in two rituximab refractory cases of idiopathic inflammatory myopathies with severe interstitial lung disease.

Efficacy of obinutuzumab in two rituximab refractory cases of idiopathic inflammatory myopathies with severe interstitial lung disease.

Journal: Annals of the rheumatic diseases

Published: April 16, 2025

Treating connective tissue disease-associated interstitial lung disease - think outside the box: a perspective.

Treating connective tissue disease-associated interstitial lung disease - think outside the box: a perspective.

Journal: European respiratory review : an official journal of the European Respiratory Society

Published: March 05, 2025

One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease.

One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease.

Journal: Annals of the rheumatic diseases

Published: February 05, 2025

Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years.

Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years.

Journal: The Lancet. Respiratory medicine

Published: December 22, 2024

Showing 1-12 of 35

Last Updated: 09/26/2026